These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 32587951)

  • 1. Characterization of RNA-Binding Motif 3 (RBM3) Protein Levels and Nuclear Architecture Changes in Aggressive and Recurrent Prostate Cancer.
    Carleton NM; Zhu G; Miller MC; Davis C; Kulkarni P; Veltri RW
    Cancer Rep (Hoboken); 2020 Jun; 3(3):e1237. PubMed ID: 32587951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear Shape and Architecture in Benign Fields Predict Biochemical Recurrence in Prostate Cancer Patients Following Radical Prostatectomy: Preliminary Findings.
    Lee G; Veltri RW; Zhu G; Ali S; Epstein JI; Madabhushi A
    Eur Urol Focus; 2017 Oct; 3(4-5):457-466. PubMed ID: 28753763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High RBM3 expression in prostate cancer independently predicts a reduced risk of biochemical recurrence and disease progression.
    Jonsson L; Gaber A; Ulmert D; Uhlén M; Bjartell A; Jirström K
    Diagn Pathol; 2011 Sep; 6():91. PubMed ID: 21955582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PBOV1 as a potential biomarker for more advanced prostate cancer based on protein and digital histomorphometric analysis.
    Carleton NM; Zhu G; Gorbounov M; Miller MC; Pienta KJ; Resar LMS; Veltri RW
    Prostate; 2018 May; 78(7):547-559. PubMed ID: 29520928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative alterations in nuclear structure predict prostate carcinoma distant metastasis and death in men with biochemical recurrence after radical prostatectomy.
    Khan MA; Walsh PC; Miller MC; Bales WD; Epstein JI; Mangold LA; Partin AW; Veltri RW
    Cancer; 2003 Dec; 98(12):2583-91. PubMed ID: 14669277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High RNA-binding motif protein 3 expression is an independent prognostic marker in operated prostate cancer and tightly linked to ERG activation and PTEN deletions.
    Grupp K; Wilking J; Prien K; Hube-Magg C; Sirma H; Simon R; Steurer S; Budäus L; Haese A; Izbicki J; Sauter G; Minner S; Schlomm T; Tsourlakis MC
    Eur J Cancer; 2014 Mar; 50(4):852-61. PubMed ID: 24380696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of prostate-specific antigen recurrence in men with long-term follow-up postprostatectomy using quantitative nuclear morphometry.
    Veltri RW; Miller MC; Isharwal S; Marlow C; Makarov DV; Partin AW
    Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):102-10. PubMed ID: 18199716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture.
    Jeyapala R; Savio AJ; Olkhov-Mitsel E; Kamdar S; Zhao F; Cuizon C; Liu RSC; Zlotta A; Fleshner N; van der Kwast T; Bapat B
    Eur Urol Oncol; 2019 May; 2(3):231-238. PubMed ID: 31200836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Akt Activation Correlates with Snail Expression and Potentially Determines the Recurrence of Prostate Cancer in Patients at Stage T2 after a Radical Prostatectomy.
    Chen WY; Hua KT; Lee WJ; Lin YW; Liu YN; Chen CL; Wen YC; Chien MH
    Int J Mol Sci; 2016 Jul; 17(8):. PubMed ID: 27455254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PPM1D as a novel biomarker for prostate cancer after radical prostatectomy.
    Jiao L; Shen D; Liu G; Jia J; Geng J; Wang H; Sun Y
    Anticancer Res; 2014 Jun; 34(6):2919-25. PubMed ID: 24922655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased mediator complex subunit CDK19 expression associates with aggressive prostate cancer.
    Becker F; Joerg V; Hupe MC; Roth D; Krupar R; Lubczyk V; Kuefer R; Sailer V; Duensing S; Kirfel J; Merseburger AS; Brägelmann J; Perner S; Offermann A
    Int J Cancer; 2020 Jan; 146(2):577-588. PubMed ID: 31271443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.
    Klein EA; Cooperberg MR; Magi-Galluzzi C; Simko JP; Falzarano SM; Maddala T; Chan JM; Li J; Cowan JE; Tsiatis AC; Cherbavaz DB; Pelham RJ; Tenggara-Hunter I; Baehner FL; Knezevic D; Febbo PG; Shak S; Kattan MW; Lee M; Carroll PR
    Eur Urol; 2014 Sep; 66(3):550-60. PubMed ID: 24836057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD147 expression predicts biochemical recurrence after prostatectomy independent of histologic and pathologic features.
    Bauman TM; Ewald JA; Huang W; Ricke WA
    BMC Cancer; 2015 Jul; 15():549. PubMed ID: 26209327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p300 (histone acetyltransferase) biomarker predicts prostate cancer biochemical recurrence and correlates with changes in epithelia nuclear size and shape.
    Isharwal S; Miller MC; Marlow C; Makarov DV; Partin AW; Veltri RW
    Prostate; 2008 Jul; 68(10):1097-104. PubMed ID: 18459105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic accuracy of Prostate Health Index and urinary Prostate Cancer Antigen 3 in predicting pathologic features after radical prostatectomy.
    Cantiello F; Russo GI; Ferro M; Cicione A; Cimino S; Favilla V; Perdonà S; Bottero D; Terracciano D; De Cobelli O; Morgia G; Damiano R
    Urol Oncol; 2015 Apr; 33(4):163.e15-23. PubMed ID: 25575715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy.
    Geybels MS; Wright JL; Bibikova M; Klotzle B; Fan JB; Zhao S; Feng Z; Ostrander EA; Lin DW; Nelson PS; Stanford JL
    Clin Epigenetics; 2016; 8():97. PubMed ID: 27651837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A four-gene transcript score to predict metastatic-lethal progression in men treated for localized prostate cancer: Development and validation studies.
    Cheng A; Zhao S; FitzGerald LM; Wright JL; Kolb S; Karnes RJ; Jenkins RB; Davicioni E; Ostrander EA; Feng Z; Fan JB; Dai JY; Stanford JL
    Prostate; 2019 Oct; 79(14):1589-1596. PubMed ID: 31376183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Significance of Accurate Determination of Gleason Score for Therapeutic Options and Prognosis of Prostate Cancer.
    Helpap B; Ringli D; Tonhauser J; Poser I; Breul J; Gevensleben H; Seifert HH
    Pathol Oncol Res; 2016 Apr; 22(2):349-56. PubMed ID: 26563277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer.
    Jögi A; Brennan DJ; Rydén L; Magnusson K; Fernö M; Stål O; Borgquist S; Uhlen M; Landberg G; Påhlman S; Pontén F; Jirström K
    Mod Pathol; 2009 Dec; 22(12):1564-74. PubMed ID: 19734850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA Ploidy as surrogate for biopsy gleason score for preoperative organ versus nonorgan-confined prostate cancer prediction.
    Isharwal S; Miller MC; Epstein JI; Mangold LA; Humphreys E; Partin AW; Veltri RW
    Urology; 2009 May; 73(5):1092-7. PubMed ID: 19193410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.